olanzapine pamoate
Long-acting injectable antipsychotic • Brands: ZYPREXA RELPREVV
Last reviewed: 2025-12-30
General information
- Class: Long-acting injectable antipsychotic
- Common US brands: ZYPREXA RELPREVV
- Long-acting injectable formulation available.
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Long-acting injectable olanzapine formulation (D2/5-HT2A antagonist with strong H1 and muscarinic activity) used for schizophrenia maintenance; requires post-injection observation due to PDSS risk.
Metabolism & Half‑life
- Metabolism: CYP1A2, CYP2D6 (minor)
- Half‑life: Steady-state mean 720 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Long‑acting injectable (LAI)
Monitoring highlights
- —
Sources
- ZYPREXA RELPREVV (olanzapine pamoate) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
- ZYPREXA (olanzapine) label — DailyMed (2025)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management — CNS Drugs (2015)